Literature DB >> 23435295

Treatment-related changes in serum lipids and inflammation: clinical relevance remains unclear. Analyses from the Women's Interagency HIV study.

Christina M Parrinello1, Alan L Landay, Howard N Hodis, Stephen J Gange, Philip J Norris, Mary Young, Kathryn Anastos, Phyllis C Tien, Xiaonan Xue, Jason Lazar, Lorie Benning, Russell P Tracy, Robert C Kaplan.   

Abstract

Among 127 HIV-infected women, the magnitude of high-density lipoprotein cholesterol (HDLc) increases after HAART initiation predicted the magnitude of concurrent decreases in inflammation biomarkers. After HAART initiation, changes in low-density lipoprotein cholesterol (LDLc) and inflammation were unrelated. In the same population, predicted risk of coronary heart disease, based upon levels of standard clinical risk factors, was similar before and after HAART. Thus, it remains unknown whether short-term treatment-related changes in standard risk factors may appreciably change risk of cardiovascular disease (CVD).

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23435295      PMCID: PMC3909663          DOI: 10.1097/QAD.0b013e32835fd8a9

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  6 in total

1.  Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

Authors: 
Journal:  Circulation       Date:  2002-12-17       Impact factor: 29.690

2.  Prediction of coronary heart disease using risk factor categories.

Authors:  P W Wilson; R B D'Agostino; D Levy; A M Belanger; H Silbershatz; W B Kannel
Journal:  Circulation       Date:  1998-05-12       Impact factor: 29.690

3.  Ten-year predicted coronary heart disease risk in HIV-infected men and women.

Authors:  Robert C Kaplan; Lawrence A Kingsley; A Richey Sharrett; Xiuhong Li; Jason Lazar; Phyllis C Tien; Wendy J Mack; Mardge H Cohen; Lisa Jacobson; Stephen J Gange
Journal:  Clin Infect Dis       Date:  2007-09-12       Impact factor: 9.079

4.  Atherosclerosis is associated with multiple pathogenic mechanisms in HIV-infected antiretroviral-naive or treated individuals.

Authors:  Stefania Piconi; Serena Parisotto; Giuliano Rizzardini; Simone Passerini; Paola Meraviglia; Monica Schiavini; Fosca Niero; Mara Biasin; Paolo Bonfanti; Elena Delfina Ricci; Daria Trabattoni; Mario Clerici
Journal:  AIDS       Date:  2013-01-28       Impact factor: 4.177

5.  Association of subclinical atherosclerosis with lipid levels amongst antiretroviral-treated and untreated HIV-infected women in the Women's Interagency HIV study.

Authors:  Christina M Parrinello; Alan L Landay; Howard N Hodis; Stephen J Gange; Philip J Norris; Mary Young; Kathryn Anastos; Phyllis C Tien; Xiaonan Xue; Jason Lazar; Lorie Benning; Russell P Tracy; Robert C Kaplan
Journal:  Atherosclerosis       Date:  2012-10-05       Impact factor: 5.162

6.  Potential cardiovascular disease risk markers among HIV-infected women initiating antiretroviral treatment.

Authors:  Robert C Kaplan; Alan L Landay; Howard N Hodis; Stephen J Gange; Philip J Norris; Mary Young; Kathryn Anastos; Phyllis C Tien; Xiaonan Xue; Jason Lazar; Christina M Parrinello; Lorie Benning; Russell P Tracy
Journal:  J Acquir Immune Defic Syndr       Date:  2012-08-01       Impact factor: 3.731

  6 in total
  4 in total

Review 1.  Risk of coronary heart disease in patients with HIV infection.

Authors:  Markella V Zanni; Judith Schouten; Steven K Grinspoon; Peter Reiss
Journal:  Nat Rev Cardiol       Date:  2014-10-21       Impact factor: 32.419

Review 2.  Metabolic and Cardiovascular Complications in HIV/HCV-Co-infected Patients.

Authors:  Roger Bedimo; Oladapo Abodunde
Journal:  Curr HIV/AIDS Rep       Date:  2016-12       Impact factor: 5.071

3.  Changes in metabolic syndrome status after initiation of antiretroviral therapy.

Authors:  Supriya Krishnan; Jeffrey T Schouten; Benjamin Atkinson; Todd T Brown; David A Wohl; Grace A McComsey; Marshall J Glesby; Cecilia Shikuma; Richard Haubrich; Denise L Jacobson
Journal:  J Acquir Immune Defic Syndr       Date:  2015-01-01       Impact factor: 3.731

4.  Metabolic Syndrome in HIV/HCV Co-infected Patients.

Authors:  Lauren F Collins; Ruth O Adekunle; Emily J Cartwright
Journal:  Curr Treat Options Infect Dis       Date:  2019-12-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.